Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (416)
  • Open Access

    REVIEW

    Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy

    QIUQIANG CHEN1,*, XUEJUN GUO2, WENXUE MA3,*

    Oncology Research, Vol.32, No.1, pp. 49-60, 2024, DOI:10.32604/or.2023.042383

    Abstract Cancer immunotherapy has emerged as a promising strategy for the treatment of cancer, with the tumor microenvironment (TME) playing a pivotal role in modulating the immune response. CD47, a cell surface protein, has been identified as a crucial regulator of the TME and a potential therapeutic target for cancer therapy. However, the precise functions and implications of CD47 in the TME during immunotherapy for cancer patients remain incompletely understood. This comprehensive review aims to provide an overview of CD47’s multifaced role in TME regulation and immune evasion, elucidating its impact on various types of immunotherapy outcomes, including checkpoint inhibitors and… More > Graphic Abstract

    Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy

  • Open Access

    ARTICLE

    Inhibition of Ehrlich ascites carcinoma growth by melatonin: Studies with micro-CT

    SEHER YILMAZ1,2,*, ZÜLEYHA DOĞANYIĞIT3, MERT OCAK4, EVRIM SUNA ARIKAN SÖYLEMEZ5, ASLI OKAN OFLAMAZ3, SÜMEYYE UÇAR6, ŞÜKRÜ ATEŞ1, AMMAD AHMAD FAROOQI7

    Oncology Research, Vol.32, No.1, pp. 175-185, 2024, DOI:10.32604/or.2023.042350

    Abstract Melatonin is a versatile indolamine synthesized and secreted by the pineal gland in response to the photoperiodic information received by the retinohypothalamic signaling pathway. Melatonin has many benefits, such as organizing circadian rhythms and acting as a powerful hormone. We aimed to show the antitumor effects of melatonin in both in vivo and in vitro models through the mammalian target of rapamycin (mTOR) signaling pathway and the Argyrophilic Nucleolar Regulatory Region (AgNOR), using the Microcomputed Tomography (Micro CT). Ehrlich ascites carcinoma (EAC) cells were administered into the mice by subcutaneous injection. Animals with solid tumors were injected intraperitoneally with 50… More > Graphic Abstract

    Inhibition of Ehrlich ascites carcinoma growth by melatonin: Studies with micro-CT

  • Open Access

    REVIEW

    Recent updates on nano-phyto-formulations based therapeutic intervention for cancer treatment

    ABHISHEK WAHI1, MAMTA BISHNOI2, NEHA RAINA1, MEGHNA AMRITA SINGH1, PIYUSH VERMA1, PIYUSH KUMAR GUPTA3,4, GINPREET KAUR5, HARDEEP SINGH TULI6,*, MADHU GUPTA1,*

    Oncology Research, Vol.32, No.1, pp. 19-47, 2024, DOI:10.32604/or.2023.042228

    Abstract Cancer is a leading cause of death globally, with limited treatment options and several limitations. Chemotherapeutic agents often result in toxicity which long-term conventional treatment. Phytochemicals are natural constituents that are more effective in treating various diseases with less toxicity than the chemotherapeutic agents providing alternative therapeutic approaches to minimize the resistance. These phytoconstituents act in several ways and deliver optimum effectiveness against cancer. Nevertheless, the effectiveness of phyto-formulations in the management of cancers may be constrained due to challenges related to inadequate solubility, bioavailability, and stability. Nanotechnology presents a promising avenue for transforming current cancer treatment methods through the… More > Graphic Abstract

    Recent updates on nano-phyto-formulations based therapeutic intervention for cancer treatment

  • Open Access

    ARTICLE

    Identification of lncRNAs associated with T cells as potential biomarkers and therapeutic targets in lung adenocarcinoma

    LU SUN1,2, HUAICHENG TAN1, TING YU3, RUICHAO LIANG4,*

    Oncology Research, Vol.31, No.6, pp. 967-988, 2023, DOI:10.32604/or.2023.042309

    Abstract Lung adenocarcinoma (LUAD) is the most common and deadliest subtype of lung cancer. To select more targeted and effective treatments for individuals, further advances in classifying LUAD are urgently needed. The number, type, and function of T cells in the tumor microenvironment (TME) determine the progression and treatment response of LUAD. Long noncoding RNAs (lncRNAs), may regulate T cell differentiation, development, and activation. Thus, our aim was to identify T cell-related lncRNAs (T cell-Lncs) in LUAD and to investigate whether T cell-Lncs could serve as potential stratifiers and therapeutic targets. Seven T cell-Lncs were identified to further establish the T… More >

  • Open Access

    ARTICLE

    Polo-like kinase 1 suppresses lung adenocarcinoma immunity through necroptosis

    PENGCHENG ZHANG1,#,*, XINGLONG ZHANG2,#, YONGFU ZHU3, YIYI CUI1, JING XU4, WEIPING ZHANG1,*

    Oncology Research, Vol.31, No.6, pp. 937-953, 2023, DOI:10.32604/or.2023.030933

    Abstract Polo-like kinase 1 (PLK1) plays a crucial role in cell mitosis and has been associated with necroptosis. However, the role of PLK1 and necroptosis in lung adenocarcinoma (LA) remains unclear. In this study, we analyzed The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression databases to evaluate the prognostic value and mechanistic role of PLK1 in LA. PLK1 was found to be highly expressed in LA and was positively associated with advanced disease staging and poor survival outcomes. Functional enrichment analysis showed that PLK1 was involved in cell mitosis, neurotransmitter transmission, and drug metabolism. Further analysis using single-sample gene set enrichment… More > Graphic Abstract

    Polo-like kinase 1 suppresses lung adenocarcinoma immunity through necroptosis

  • Open Access

    ARTICLE

    CircUCP2 promotes the tumor progression of non-small cell lung cancer through the miR-149/UCP2 pathway

    WEI DU1, FANG YIN1, YATING ZHONG1, MINJIE LUO1, ZHEN WANG2, PENG LIN2, QING LIU2,*, HAN YANG2,*

    Oncology Research, Vol.31, No.6, pp. 929-936, 2023, DOI:10.32604/or.2023.030611

    Abstract Non-small cell lung cancer (NSCLC) is a highly lethal cancer, and better treatments are urgently needed. Many studies have implicated circular RNAs (circRNAs) in the progression of multiple malignant tumors. Nonetheless, the functions of circRNAs in NSCLC remain unclear. To study new targets for the treatment of NSCLC, circRNA expression profiling was performed on NSCLC tissues and para-carcinoma nonmalignant tissues. RNA was isolated and used for circRNA sequencing. Biological studies were performed in vitro and in vivo to determine the functions of circRNAs in NSCLC, including their functions in cell proliferation and migration. How circRNAs function in NSCLC was explored… More > Graphic Abstract

    CircUCP2 promotes the tumor progression of non-small cell lung cancer through the miR-149/UCP2 pathway

  • Open Access

    ARTICLE

    A novel isoxazole compound CM2-II-173 inhibits the invasive phenotype of triple-negative breast cancer cells

    EUN SOOK KIM1, SANGHEE KIM2, AREE MOON1,*

    Oncology Research, Vol.31, No.6, pp. 867-875, 2023, DOI:10.32604/or.2023.030411

    Abstract Invasion and metastasis are important hallmarks of breast cancer and are the leading cause of patient mortality. Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer characterized by a poor prognosis and a lack of effective targeted therapies. The present study investigated the inhibitory effect of a novel FTY720 derivative on the invasive phenotype of TNBC cells. Here, we showed that a novel compound with an isoxazole ring, 4-(3-Decylisoxazol-5-yl)-1-hydroxy-2-(hydroxymethyl)butan-2-aminium chloride (CM2-II-173), significantly inhibited invasiveness of MDA-MB-231 TNBC cells. Expression of matrix metalloproteinase (MMP)-9 and invasiveness of MCF10A normal breast cells induced by sphingosine-1-phosphate (S1P) were reduced by CM2-II-173… More >

  • Open Access

    ARTICLE

    Long non-coding RNA H19 promotes proliferation in hepatocellular carcinoma cells via H19/miR-107/CDK6 axis

    ARCHITTAPON NOKKEAW1,2,3,#, PANNATHON THAMJAMRASSRI1,2,3,#, NAPHAT CHANTARAVISOOT1,4, PISIT TANGKIJVANICH1,2,*, CHAIYABOOT ARIYACHET1,2,*

    Oncology Research, Vol.31, No.6, pp. 989-1005, 2023, DOI:10.32604/or.2023.030395

    Abstract Hepatocellular carcinoma (HCC) is the leading cause of cancer death worldwide; nevertheless, current therapeutic options are limited or ineffective for many patients. Therefore, elucidation of molecular mechanisms in HCC biology could yield important insights for the intervention of novel therapies. Recently, various studies have reported dysregulation of long non-coding RNAs (lncRNAs) in the initiation and progression of HCC, including H19; however, the biological function of H19 in HCC remains unclear. Here, we show that knockdown of H19 disrupted HCC cell growth, impaired the G1-to-S phase transition, and promoted apoptosis, while overexpression of H19 yielded the opposite results. Screening for expression… More > Graphic Abstract

    Long non-coding RNA H19 promotes proliferation in hepatocellular carcinoma cells via H19/miR-107/CDK6 axis

  • Open Access

    ARTICLE

    Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer

    SUNG HEE LIM1,#, HEE JIN CHO1,2,3,#, KYOUNG-MEE KIM4, HO YEONG LIM1, WON KI KANG1, JEEYUN LEE1, YOUNG SUK PARK1, HEE CHEOL KIM5,*, SEUNG TAE KIM1,*

    Oncology Research, Vol.31, No.6, pp. 855-866, 2023, DOI:10.32604/or.2023.030374

    Abstract Background: Although bevacizumab is an important treatment for metastatic colorectal cancer (CRC), not all patients with CRC benefit from it; in unselected patient populations, only modest survival benefits have been reported. Methods: We evaluated clinical outcomes in 110 patients using comprehensive molecular characterization to identify biomarkers for a response to bevacizumab-containing treatment. The molecular analysis comprised whole-exome sequencing, ribonucleic acid sequencing, and a methylation array on patient tissues. Results: Genomic and molecular characterization was successfully conducted in 103 patients. Six of 103 CRC samples were hypermutated, and none of the non-hypermutant tumors were microsatellite unstable. Among those 103 patients, 89… More >

  • Open Access

    ARTICLE

    Deoxynortryptoquivaline: A unique antiprostate cancer agent

    YOHKO YAMAZAKI1,*, MANABU KAWADA2, ISAO MOMOSE1

    Oncology Research, Vol.31, No.6, pp. 845-853, 2023, DOI:10.32604/or.2023.030266

    Abstract The androgen receptor (AR) is a critical target in all the clinical stages of prostate cancer. To identify a new AR inhibitor, we constructed a new screening system using the androgen-dependent growth of prostate cancer cell lines as a screening indicator. We screened 50,000 culture broths of microorganisms using this screening system and found that the fermentation broth produced by a fungus inhibited androgen-dependent growth of human prostate cancer LNCaP cells without cytotoxicity. Purification of this culture medium was performed, and this resulted in deoxynortryptoquivaline (DNT) being identified as a novel inhibitor of AR function. DNT showed potent inhibition of… More > Graphic Abstract

    Deoxynortryptoquivaline: A unique antiprostate cancer agent

Displaying 71-80 on page 8 of 416. Per Page